Additional file 1: of Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up

Methods. Immunohistochemical analysis for Ki-67. Figure S1. Distribution of PAM50 subtypes within subgroups based on HR and HER2 status. Bars represent percentage of total in each HR/HER2− group. Number is displayed on top of the bar. Figure S2. ROR score within each of the PAM50 subtypes for all patients (R statistical software package). Figure S3. Kaplan-Meier plots of BCSS (S3a) and DDFS (S3b) according to HR/HER2 subtypes in all 653 patients (a) and according to PAM50 subtypes within different HR/HER2 (b–e) subgroups. p Values were derived from log-rank tests. Figure S4. Kaplan-Meier plots of BCSS according to ROR categories for node-negative (a) and node-positive (b) HR+/HER2− patients. p Values were derived from log-rank tests. Figure S5. Kaplan-Meier plots of BCSS (a and b) and DDFS (c and d) according to ROR categories for node-negative luminal A HR+/HER2− patients with no adjuvant treatment (a, c) or treated with tamoxifen only (b, d). p Values were derived from log-rank tests. Figure S6. Correlation between Ki-67 expression and ROR score for the HR+/HER2− patients. ρ = 0.62, p

方法：Ki-67免疫组化分析。
补充图S1：基于激素受体（Hormone Receptor, HR）和人表皮生长因子受体2（Human Epidermal Growth Factor Receptor 2, HER2）状态的亚组内PAM50亚型分布。柱状图代表各HR/HER2-组的总占比，柱体上方标注具体数值。
补充图S2：所有患者的各PAM50亚型对应的复发风险评分（Recurrence Risk Score, ROR），分析采用R统计软件包（R statistical software package）完成。
补充图S3：全部653例患者中，按HR/HER2亚型划分的乳腺癌特异性生存率（Breast Cancer-Specific Survival, BCSS，图S3a）与无远处疾病生存期（Distant Disease-Free Survival, DDFS，图S3b）的Kaplan-Meier曲线（Kaplan-Meier plot）；以及按不同HR/HER2亚组内的PAM50亚型划分的Kaplan-Meier曲线（图S3b~e）。P值通过对数秩检验（log-rank test）计算得到。
补充图S4：针对HR+/HER2-患者，按ROR评分分组划分的BCSS的Kaplan-Meier曲线，其中(a)为淋巴结阴性亚组，(b)为淋巴结阳性亚组。P值通过对数秩检验计算得到。
补充图S5：针对未接受辅助治疗（图S5a、c）或仅接受他莫昔芬治疗（图S5b、d）的淋巴结阴性腔面A型HR+/HER2-患者，按ROR评分分组划分的BCSS（图S5a、b）与DDFS（图S5c、d）的Kaplan-Meier曲线。P值通过对数秩检验计算得到。
补充图S6：HR+/HER2-患者的Ki-67表达水平与ROR评分的相关性分析，相关系数ρ=0.62，P值